小包装全氟丙烷气体动力学实验研究

为检验塑料小包装全氟丙烷气体（C3F8）在不同包装和储存方法时浓度变化，将装有5～7mlC3F8的聚氯乙烯小袋，根据不同储藏温度和外包装方法随机分成四组：（1）22℃聚乙烯外包装，（2）36℃聚乙烯外包装，（3）22℃铝箔真空外包装，（4）-29℃聚乙烯外包装；每一组C3F8小袋气体存放一定时间后，应用气相色谱分析方法进行浓度测量。结果：第3组C3F8浓度最高和稳定，第2组浓度随放置时间降低最明显，第4组是临床应用气体的储藏和包装方法，其30天样本浓度和第3组相等，但放置一年时浓度降低。结果显示：塑料小包装C3F8予以铝箔真空外包装是一种可行的方法，利于C3F8运输和普及；聚乙烯外包装的C3F8，应放在-29℃保存，时间不超过一年。     

Lesbianism in China

Lesbianism in China has a long but usually hidden history. This paper examines the historical and literary sources of the past to illustrate the history of lesbianism and then turns to a survey of lesbianism in the China of today. As in the past, lesbianism remains more or less hidden, and comes to light only occasionally. Data for contemporary China comes from a visit to an institution for delinquent young women, recent police records, and contemporary fiction. It has only been in the past 4 or 5 years that it was possible to talk about lesbianism and most lesbians are fearful of becoming identified.     

诺迪康对心脏活动的药理学作用

目的 :探讨诺迪康对心脏活动的药理学作用。方法 :运用 ms2 0 0 0多媒体生物信号处理系统 ,经 Straub法制备离体蛙心灌流标本并检测心脏活动 ,利用血流动力学方法检测家兔的心室活动等相关指标。结果 :2 0 9mg/L 诺迪康组的心肌收缩力增强 4 0 .38% (n =2 1,P <0 .0 0 1) ,4 18mg/L 诺迪康组的心肌收缩力增强 76 .4 4 % (n =17,P <0 .0 5 ) ,6 2 7mg/L 诺迪康组的心肌收缩力增强 10 4 .95 % (n =2 5 ,P <0 .0 1) ,对照组的心肌收缩力无明显变化 (n =2 5 ,P >0 .5 ) ;三个实验组及对照组对离体蛙心率均无作用 ,P >0 .0 5 ;家兔血流动力学方面 ,诺迪康组的 dp/dtmax增加了 2 1.0 8% (n =10 ,P <0 .0 5 ) ,其他各指标在对照组及诺迪康组均未见显著变化。结论 :诺迪康能增强心肌收缩力且有明显的剂量效应关系 ,可加速心肌的收缩速度但对心肌舒张无明显影响     

温针灸治疗颞下颌关节功能紊乱病36例

目的:比较温针灸与口服西药治疗颞下颌关节功能紊乱病的疗效。方法:治疗组36例取下关、牵正、颊车、阿是穴、合谷(双)行温针灸,对照组口服地西泮、吲哚美辛。结果:治疗组治愈率80·6%、总有效率100%,对照组治愈率40·6%、总有效率78·1%,两组有非常显著性差异(P<0.01)。结论:温针灸治疗颞下颌关节功能紊乱病方法简单,疗效显著。     

二尖瓣置换术围手术期硝普钠的应用

本文介绍了20例二尖瓣置换术病人围手术期使用硝普钠的经验。术中和术后早期使用硝普钠可降低肾素-血管紧张素系统的活性、减轻外周血管阻力和后负荷,增强泵血功能,从而使心脏指数升高,降低术后高血压和肺水种的发生率。体外循环停止后,硝普钠与低浓度升压药并用可增强心肌收缩力,预防低排综合征     

人体膀胱移行上皮癌细胞系(TSB-90,TSB-91)的建立及其生物学特性

从1例膀胱癌患者的癌组织培养中，分离得到2个不同生长特性的悬浮生长型细胞系，定名为TSB-90和TSB-91。在培养过程中，对其生物学特性进行了细胞和亚细胞水平的探讨，并进行了核型分析。发现2个细胞系核型的演化趋势有明显差异，生物学特性也不尽相同。这可能与膀胱癌组织中细胞的遗传异质性和分化程度有关。对其机制和细节有待进一步深入研究。     

谈谈如何设计教学内容

教学内容的设计是教学设计中的重要组成部分，从针对学生的具体情况，合理选择教学内容；把握知识结构体系，使教学内容呈现整体性；客观分析教学内容，抓住重点与中心；突破教材教学内容，实现教学内容的延伸4个方面，探讨如何设计教学内容。     

Increase of prolactin mRNA in the rat hypothalamus after intracerebroventricular injection of VIP or PACAP

Vasoactive intestinal peptide (VIP), the structurally homologous pituitary adenylate cyclase-activating peptide (PACAP) and the pituitary hormone, prolactin (PRL) enhance rapid eye movement sleep (REMS). VIP and PACAP are both inducers of PRL gene expression and release in the pituitary gland. Little is known about PRL regulation in the brain although it is hypothesized that the REMS-promoting activity of i.c.v. administered VIP may be mediated via the activation of cerebral PRL. To test whether VIP or PACAP in fact increase intracerebral mRNA, the peptides (VIP: 30 or 300 pmol; PACAP: 220 pmol) were injected i.c.v. into rats at dark onset. 1 h later, cDNA was synthesized from purified hypothalamic mRNA. Standardized amounts were analysed for PRL using the polymerase chain reaction followed by Southern blotting and hybridization. Compared with β-actin mRNA levels, both VIP and PACAP increased PRL mRNA levels in a dose-dependent fashion though VIP was more effective on a molar basis. The previously reported alternatively spliced PRL mRNA (lacking exon 4) was not detected. The data support the hypothesis that the REMS-promoting activity of central VIP and PACAP might be mediated by cerebral PRL.     

The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.

BACKGROUND AND PURPOSE: The potential risk of prolongation of treatment time in cervical cancer has been reported for many low-dose rate (LDR) studies, with an estimated loss of local control ranging from 0.3 to 1.6% per day of treatment prolongation. Since the treatment schedule for fractionated high-dose rate intracavitary brachytherapy (HDRICB) is not directly comparable with that for low-dose rate studies, this report aims to evaluate the adverse effect of treatment prolongation specifically for cervical cancer treated with HDRICB. MATERIAL AND METHODS: From September 1992 to December 1997, 257 patients diagnosed with uterine cervical cancer (35 Ib, 26 IIa, 122 IIb, 10 IIIa, 57 IIIb, 7 IVa), who underwent external radiotherapy combined with between two and four courses of HDRICB and a minimum of 3 years of follow-up (median 57 months), were analyzed. Treatment consisted of irradiation of the whole pelvis with 44-45 Gy consisting of 22-25 fractions by 5 weeks, with the dose boosted to 54-58 Gy (with central shielding) for patients diagnosed as FIGO stage IIb-IVa bilateral parametrial disease. HDRICB was performed using an Ir-192 remote afterloading technique at 1-week intervals. The standard prescribed dose for each course of HDRICB was 7.2 Gy to point A for three insertions (before July 1995), or 6.0 Gy to point A for four insertions (after July 1995). Total prescribed point A doses (external beam radiotherapy+HDRICB) ranged from 58 to 71.6 Gy (median, 65.6 Gy) for stage IB-IIA, while analogous dosage for larger lesions (stage IIb-IVa) ranged from 59 to 75.6 Gy (median, 65.6 Gy). Kaplan-Meier and multivariate analyses were used to test the effect of treatment time on pelvic control rate (PCR) and cause-specific survival (CSS) at 5 years. RESULTS: Median treatment time was 63 days. For all stages of disease, the 5-year CSS and PCR were significantly different comparing treatment times of less than and greater than or equal to 63 days [83% and 65% (P=0.004], 93% and 83% (P=0.02), respectively]. These associations were also significant for stage Ib/IIa [97% and 79% (P=0.01), and 100% and 87% (P=0.02), respectively), but not for stage IIb [75% and 72% (P=0.79), and 93% and 87% (P=0.83), respectively] or stage III [66% and 49% (P=0.2), and 83% and 72% (P=0.21), respectively]. Multivariate analysis identified three prognostic factors for CSS, stage (P<0.001), tumor response to external RT (P=0.001), and overall treatment time (OTT; P=0.006). Prognostic factors for pelvic failure were stage (P<0.001), tumor response to external RT (P=0.001), and OTT (P=0.03). Prolongation of treatment time resulted in a daily decrease in pelvic control rate of 0.67% overall, and 0.43% for stage Ib-IIa, 0.57% for stage IIb, and 0.73% for stage III patients. CONCLUSION: Analysis of the data from the current study demonstrates that the adverse effect of treatment prolongation was observed later in the treatment course for the high-dose rate (HDR) series compared to the LDR analog, however, treatment-time prolongation still negatively influenced the cause-specific survival and pelvic control rate for both dosage groups.